AI-generated summary
The authors report a secondary analysis of an 8-week randomized trial comparing bright light therapy, fluoxetine, their combination, and placebo in nonseasonal major depressive disorder. Quality of life scores improved across all arms, but no significant differences between treatment groups were found, and most participants still had impaired quality of life at 8 weeks.
- Who or what was studied
- Patients with nonseasonal major depressive disorder
- Limits stated in the abstract
- The abstract reports no significant differences between treatment arms and does not describe a placebo-controlled effect size or long-term follow-up.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Bright light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.